Spasm Clinical Trial
— NAVIGATOROfficial title:
Dual-acquisition of Noninvasive Cardiac Imaging in Vasospastic Angina Korean Registry
NCT number | NCT03570671 |
Other study ID # | NAVIGATOR |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2018 |
Est. completion date | July 1, 2021 |
With regard to the characteristics of spasm segment, had been clearly described by other
invasive imaging methods including intravascular ultrasound and optical coherence tomography.
However, there is potential risk during these invasive procedures, such as severe myocardial
ischemia or fatal arrhythmia.
Presently available imaging test for coronary artery disease in multi detector-row computed
tomography angiography (MDCTA) evaluation has high diagnostic accuracy to evaluate coronary
artery stenosis. However, previous report assessing imaging findings or diagnostic accuracy
of MDCTA in patients with vasospastic angina (VSA) is lacking.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | July 1, 2021 |
Est. primary completion date | May 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Subject is onset of angina-like attack at rest, during effort, or during rest and effort. - Subject has chest pain between night and early morning. - Subject is scheduled to undergo MDCTA. - Subject is an acceptable candidate for CAG with an EG provocation test. - Cardiac condition: BP>90/60mmHg, ECG: sinus rhythm with regular, left ventricular ejection fraction>55%, and resting heart rate<100 beats/min. - Subject will be provided written informed consent. - Subject is willing to comply with study follow-up requirement. Exclusion Criteria: - Subject has clinical evidence of acute coronary syndrome. - Subject has evidence of significant narrowing (>50% stenosis by CAG). - Subject has clinical evidence of cardiomyopathy or valvular heart disease. - Subject is hemodynamically unstable. - Subject has a history of PCI and CABG. - Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study. - Subject has known allergy to contrast medium. - Subject has renal insufficiency (serum creatine >2.5 mg/dl). |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Dong-A University Hospital | Busan |
Lead Sponsor | Collaborator |
---|---|
Dong-A University |
Korea, Republic of,
Jin C, Kim MH, Kang EJ, Cho YR, Park TH, Lee KN, Serebruany V. Assessing Vessel Tone during Coronary Artery Spasm by Dual-Acquisition Multidetector Computed Tomography Angiography. Cardiology. 2018;139(1):25-32. doi: 10.1159/000478926. Epub 2017 Nov 23. — View Citation
Kang EJ, Kim MH, De Jin C, Seo J, Kim DW, Yoon SK, Park TH, Lee KN, Choi SI, Yoon YE. Noninvasive detection of coronary vasospastic angina using a double-acquisition coronary CT angiography protocol in the presence and absence of an intravenous nitrate: a pilot study. Eur Radiol. 2017 Mar;27(3):1136-1147. doi: 10.1007/s00330-016-4476-2. Epub 2016 Jul 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Tolerability | MDCTA procedure: all subjects will undergo MDCTA without a vasodilator ("initial CT") in the early morning before the ergonovine provocation spasm test. Subsequent "IV nitrate CT" will be allowed at a 3-day washout period after the first contrast usage. The scan protocol for the IV nitrate CT is as follows: during continuous injection of the intravenous vasodilating agent (isosorbidedinitrate 2 mg/hr), blood pressure will be checked every 2 minutes. When both the systolic and diastolic blood pressure decrease by 10 mmHg in comparison to the initial value, the CT scan initiate and images will be acquired during the nitrate infusion. Investigators define the positive criteria for VSA on MDCTA as follows: Significant stenosis (= 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or Diffuse small diameter (< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT. |
3 days | |
Secondary | Coronary vessel distensibility | To evaluate the extent of coronary vessel distensibility by dual-acquisition of cardiac MDCTA in patients with VSA | 3 days | |
Secondary | Cutoff value of coronary vessel distensibility index | To consider the cutoff value of coronary vessel distensibility index (CVDI) to predict the coronary spasm induced angina-like attacks. Investigators define the CVDI as following formulas: CVDI-CSA (cross-section area)= [(CSA_IV nitrate - CSA_initial) / CSA_IV nitrate]?100% or CVDI-D (diameter)= [(D_IV nitrate - D_initial) / D_IV nitrate]?100%. |
3 days | |
Secondary | Incidence of multi-vessel spasm | To examine the incidence of multi-vessel coronary spasm by MDCTA. | 3 days | |
Secondary | Diagnostic accuracy of MDCTA | To determine the diagnostic accuracy of MDCTA modalities for detection of VSA. | 3 days | |
Secondary | Characteristics of spasm-related coronary artery segment | To describe the characteristics of spasm-related coronary artery segment including vessel remodeling, plaque composition and stenosis degree. | 3 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02814565 -
Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin
|
Phase 3 | |
Active, not recruiting |
NCT06441253 -
Development and Evaluation of a Portable Wedge Device for Calf Stretching to Alleviate Strain and Spasms
|
N/A | |
Completed |
NCT01155167 -
Topical Radial Artery Vasodilation
|
Phase 2/Phase 3 | |
Completed |
NCT00001784 -
Mexiletine for the Treatment of Focal Dystonia
|
Phase 2 | |
Completed |
NCT00001550 -
Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
|
Phase 1 | |
Completed |
NCT00246389 -
An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm
|
Phase 4 |